TAVNEOS

Indicated For

Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA), ANCA-associated vasculitis

About This Medication

# TAVNEOS Patient Assistance Program Guide: Getting Avacopan at Low Cost ## What is TAVNEOS? TAVNEOS (avacopan) is a prescription medication made by Amgen used to treat serious conditions affecting blood vessels, including: - Granulomatosis with polyangiitis (GPA) - Microscopic polyangiitis (MPA) - ANCA-associated vasculitis If cost is preventing you from getting this medication, Amgen's Patient Assistance Program can help. ## Who Can Apply? ### Insurance Status You may qualify if you are: - **Uninsured** (have no health insurance) - **Underinsured** (have insurance but cannot afford your medication costs) - **Commercially insured** (eligible for a separate copay card program to reduce out-of-pocket costs) ### Income Requirements Income limits vary based on your household size and location. Contact the program directly at **(833) 828-6367** to confirm whether your income qualifies. Generally, the program serves patients with limited financial resources. ## Two Ways to Get Help ### 1. Patient Assistance Program (For Uninsured/Underinsured Patients) If you have no insurance or cannot afford your medication even with insurance, this program may provide TAVNEOS at no cost or reduced cost. ### 2. Copay Card Program (For Commercially Insured Patients) If you have private insurance, a separate copay card program is available to lower your out-of-pocket costs. This helps reduce copayments or coinsurance. ## What You Need to Apply Have these documents ready before calling: 1. **Proof of Income** - Recent documents showing your household income, such as: - Recent tax returns - Pay stubs (last 2-3 months) - Benefit statements (Social Security, unemployment, disability) - Bank statements - Letters from employers 2. **Valid Prescription** - A current prescription from your doctor for TAVNEOS 3. **Insurance Information** (if applicable) - Policy details or proof of coverage ## How to Apply: 4 Simple Steps **Step 1: Call the Program** Contact the TAVNEOS Patient Assistance Program at **(833) 828-6367**. Representatives are available to answer questions and guide you through the process. **Step 2: Verify Your Eligibility** The program will review your income and insurance status to determine if you qualify. **Step 3: Submit Required Documents** Provide proof of income and your prescription. You can submit documents by phone, mail, or online through the program portal. **Step 4: Receive Your Medication** Once approved, your medication will be shipped directly to you or your pharmacy. There is typically no cost to you. ## Timeline: When Will I Know If I'm Approved? Most applications are reviewed within **5-10 business days** of submission. You'll be contacted by phone or email with a decision. In urgent cases, faster approval may be possible—ask the representative about expedited processing. ## Reauthorization Your assistance is not permanent. The program requires **regular reauthorization** at intervals determined by your case. You'll be notified when it's time to renew. Be prepared to resubmit income proof and other required documents. ## Getting Started **Program Contact Information:** - **Phone:** (833) 828-6367 - **Website:** https://www.tavneos.com/support/paying-for-tavneos Call during business hours with your prescription ready. If you have questions about eligibility, costs, or the application process, the representatives can help. ## Important Notes - **No biosimilar alternatives** are currently available for TAVNEOS, making this assistance program especially important. - If you have **Medicare or Medicaid**, mention this when calling—additional options may be available. - **Your doctor's office** can also help with the application process. Ask your healthcare provider if they have experience with this program. ## What If You're Denied? If your application is denied, ask the program why and what you can do next. You may be able to reapply if your circumstances change, or the team may suggest alternative resources.

Program information last verified: March 25, 2026